{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Adenocarcinomas&page=2",
    "query": {
      "condition": "Colorectal Adenocarcinomas",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Adenocarcinomas&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T12:51:53.492Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00959127",
      "title": "A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Advanced or Metastatic Biliary Cancer",
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "ARRY-438162 (MEK162), MEK inhibitor; oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2009-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00959127"
    },
    {
      "nct_id": "NCT01079780",
      "title": "Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ramucirumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2011-01-18",
      "completion_date": "2021-08-17",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 255,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 182 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01079780"
    },
    {
      "nct_id": "NCT00593060",
      "title": "Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey W. Clark, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2007-11-01",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593060"
    },
    {
      "nct_id": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BMS-986466",
          "type": "DRUG"
        },
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2023-11-09",
      "completion_date": "2024-05-13",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06024174"
    },
    {
      "nct_id": "NCT06569368",
      "title": "Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-07-10",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06569368"
    },
    {
      "nct_id": "NCT00290615",
      "title": "Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Herbert Hurwitz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2013-05-07",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00290615"
    },
    {
      "nct_id": "NCT00002796",
      "title": "Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "sodium phenylbutyrate",
          "type": "DRUG"
        },
        {
          "name": "indomethacin",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 46,
      "start_date": "1997-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002796"
    },
    {
      "nct_id": "NCT03206073",
      "title": "A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Colorectal Adenocarcinoma",
        "Refractory Cancer",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Pexa-Vec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-12-07",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03206073"
    },
    {
      "nct_id": "NCT05130060",
      "title": "A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colon Adenocarcinoma",
        "Metastatic Colorectal Adenocarcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Microsatellite Stable Colon Carcinoma",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Metastatic Rectal Adenocarcinoma",
        "Microsatellite Stable Rectal Carcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Colorectal Cancer Peptide Vaccine PolyPEPI1018",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trifluridine and Tipiracil Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-01-10",
      "completion_date": "2023-06-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05130060"
    },
    {
      "nct_id": "NCT03594630",
      "title": "Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Rectal Adenocarcinoma",
        "Stage II Rectal Cancer AJCC v8",
        "Stage IIA Rectal Cancer AJCC v8",
        "Stage IIB Rectal Cancer AJCC v8",
        "Stage IIC Rectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8",
        "Stage IIIA Rectal Cancer AJCC v8",
        "Stage IIIB Rectal Cancer AJCC v8",
        "Stage IIIC Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Resection of Rectum",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2024-03-13",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-07-24T12:51:53.492Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594630"
    }
  ]
}